Discovery
Identifying novel targets through deep biological insights into brain function and dysfunction.
Pipeline
Translating ion channel science into meaningful medicines
With deep expertise in ion channel biology, we are advancing a differentiated pipeline led by our late-stage investigational candidate, which is being studied in multiple Phase 3 trials in epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Our early-stage pipeline features Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high-need indications.
Preclinical Development
Robust pharmacology, toxicology, and proof-of-concept studies to ensure strong translational potential.
Our approach in epilepsy
We are developing a novel, potent Kv7 potassium channel opener which is in
Phase 3 Our Focus for the treatment of focal and generalized seizures. If
approved, it would be the only potassium channel opener among antiseizure
medications.
We are also exploring the Kv7 potassium channel as a key regulator of neuronal
excitability that may play a role in both epilepsy and depression, which is
increasingly being recognized as a neuronal circuit disorder.
Contact Us
Our approach in pain
We have extensive history researching the sodium channel Nav1.7 as a novel pain target, both through multiple industry collaborations and our own discovery research. This history started more than 10 years ago with the identification of a loss of function in the sodium channel Nav1.7 as the cause of congenital indifference to pain (CIP), an extremely rare autosomal recessive disorder whose carriers are unable to feel pain but are otherwise healthy. Since then, we have focused on optimizing chemistry to address the limitations of earlier drug candidates targeting Nav1.7 and believe we are now on the precipice of realizing the potential of this promising pain target with our clinical program, which is being investigated in a Phase 1 study.
Contact Us
KNOWLEDGESHIFT, LLC
Platform & Technology Development
We are continuously investing in internal platforms and enabling technologies, including digital biotechnology, data science tools, and advanced bioprocessing methods that strengthen current and future pipeline programs.
Contact Us
Projects in Pipeline
Discovery & Early Research
These projects focus on novel biological targets, innovative mechanisms of action, and next-generation technologies. Activities include target identification, assay development, biomarker exploration, and proof-of-concept studies designed to build a strong scientific foundation.
Preclinical Development
Programs in this stage are advancing through pharmacology, toxicology, and translational research. The goal is to de-risk candidates, optimize lead compounds or biologics, and generate robust data packages to support regulatory submissions.
Clinical-Stage Programs
Our clinical pipeline includes projects progressing through regulated clinical phases, supported by strong clinical strategy, data management, and compliance. These programs aim to demonstrate safety, efficacy, and clinical value across targeted patient populations.
